Hormone receptor (HR) status influences the response of a tumour to chemotherapy and the sensitivity of a tumour to combined chemotherapy and anti-HER2 therapy also differs according to HR status in the neoadjuvant setting [9–12, 31]. The gene discussed is NR4A1; the disease is neoplasm.